Resmed Inc. buy UBS Group AG
Start price
22.05.23
/
50%
€210.60
Target price
22.05.24
-
Performance (%)
-3.75%
End price
23.05.24
€202.70
Summary
This prediction ended on 23.05.24 with a price of €202.70. With a performance of -3.75%, the BUY prediction by UBS_Group_AG finished with a loss. UBS_Group_AG has a follow-up prediction for Resmed Inc. where he still thinks Resmed Inc. is a Buy. Dividends of €1.78 are taken into consideration when calculating the performance. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Resmed Inc. | 0.867% | 0.867% | -19.463% | 29.705% |
| iShares Core DAX® | -1,06 % | 5,01 % | 6,60 % | 64,71 % |
| iShares Nasdaq 100 | -2,39 % | 0,86 % | 25,79 % | 88,24 % |
| iShares Nikkei 225® | -4,36 % | 1,21 % | 41,31 % | 79,31 % |
| iShares S&P 500 | -1,78 % | 1,39 % | 21,04 % | 69,60 % |
Comments by UBS_Group_AG for this prediction
In the thread Resmed Inc. diskutieren
ResMed Inc. (NYSE: RMD) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Ratings data for RMD provided by MarketBeat
In the thread Trading Resmed Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten